Choroidal Ischemia Sparing the Watershed Zone following Intra-Arterial Chemotherapy for Retinoblastoma.

Choroidal ischemia Intra-arterial chemotherapy Retina Retinoblastoma Watershed zone

Journal

Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 19 04 2018
accepted: 12 06 2018
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 3 5 2019
Statut: ppublish

Résumé

Intra-arterial chemotherapy (IAC) has become a mainstay in the management of retinoblastoma, especially in advanced or refractory disease. However, IAC is not without complications, and chemotherapy toxic effects can lead to partial or complete choroidal ischemia, often causing vision loss. This is a case report. A 4-month-old girl with bilateral retinoblastoma was treated with secondary IAC (melphalan 5 mg) for recurrent tumor following intravenous chemotherapy. One month later, complete tumor control was achieved. However, she demonstrated broad choroidal ischemia in the nasal and temporal quadrants but sparing of the watershed zone superior and inferior to the optic disc and in the papillomacular region. Fluorescein angiography revealed poor perfusion of the choriocapillaris with visibility of the large choroidal vessels in the nasal and temporal areas but preserved perfusion of the watershed zone. The watershed zone remained intact on the 10-month follow-up, and the final visual acuity was fix and follow without strabismus. The pathophysiology of choroidal ischemia is not well understood, but the fortuitous watershed zone preservation in this case could represent uneven distribution of the chemotherapeutic drug, resulting in partial chemo-dilution of the medication in the watershed region, which represents the final downstream overlapping choroidal perfusion from both medial and lateral posterior ciliary arteries.

Identifiants

pubmed: 31049327
doi: 10.1159/000490856
pii: oop-0005-0190
pmc: PMC6489077
doi:

Types de publication

Journal Article

Langues

eng

Pagination

190-194

Références

Invest Ophthalmol Vis Sci. 2004 Mar;45(3):749-57; 748
pubmed: 14985286
Arch Ophthalmol. 2011 Nov;129(11):1407-15
pubmed: 21670326
Arch Ophthalmol. 2011 Nov;129(11):1416-21
pubmed: 21746972
Ophthalmology. 2012 Apr;119(4):843-9
pubmed: 22137042
Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2439-45
pubmed: 22427570
Ophthalmology. 2014 Jul;121(7):1453-60
pubmed: 24656794
Doc Ophthalmol. 1989 Jun;72(2):175-80
pubmed: 2582998
Am J Physiol Renal Physiol. 2017 Mar 1;312(3):F543-F548
pubmed: 27881397
Stroke. 1984 Mar-Apr;15(2):221-3
pubmed: 6701929
Int Ophthalmol. 1983 Feb;6(2):85-93
pubmed: 6832901
Br J Ophthalmol. 1994 Mar;78(3):185-90
pubmed: 8148333

Auteurs

David Arturo Ancona-Lezama (DA)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Lauren A Dalvin (LA)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.

J Antonio Lucio-Alvarez (JA)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Pascal Jabbour (P)

Department of Neurovascular and Endovascular Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Carol L Shields (CL)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Classifications MeSH